These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28029648)

  • 21. Dismantling papillary renal cell carcinoma classification: The heterogeneity of genetic profiles suggests several independent diseases.
    Marsaud A; Dadone B; Ambrosetti D; Baudoin C; Chamorey E; Rouleau E; Lefol C; Roussel JF; Fabas T; Cristofari G; Carpentier X; Michiels JF; Amiel J; Pedeutour F
    Genes Chromosomes Cancer; 2015 Jun; 54(6):369-82. PubMed ID: 25820192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications.
    Linehan WM; Ricketts CJ
    Nat Rev Urol; 2019 Sep; 16(9):539-552. PubMed ID: 31278395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics.
    Chow WH; Shuch B; Linehan WM; Devesa SS
    Cancer; 2013 Jan; 119(2):388-94. PubMed ID: 23147245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A construction and comprehensive analysis of ceRNA networks and infiltrating immune cells in papillary renal cell carcinoma.
    Fan Y; Dai F; Yuan M; Wang F; Wu N; Xu M; Bai Y; Liu Y
    Cancer Med; 2021 Nov; 10(22):8192-8209. PubMed ID: 34598322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identifying biomarkers of papillary renal cell carcinoma associated with pathological stage by weighted gene co-expression network analysis.
    He Z; Sun M; Ke Y; Lin R; Xiao Y; Zhou S; Zhao H; Wang Y; Zhou F; Zhou Y
    Oncotarget; 2017 Apr; 8(17):27904-27914. PubMed ID: 28427189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
    Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
    Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-coding RNA and gene expression analyses of papillary renal neoplasm with reverse polarity (PRNRP) reveal distinct pathological mechanisms from other renal neoplasms.
    Nemours S; Armesto M; Arestín M; Manini C; Giustetto D; Sperga M; Pivovarcikova K; Pérez-Montiel D; Hes O; Michal M; López JI; Lawrie CH
    Pathology; 2024 Jun; 56(4):493-503. PubMed ID: 38413252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
    Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal cell cancer histological subtype distribution differs by race and sex.
    Lipworth L; Morgans AK; Edwards TL; Barocas DA; Chang SS; Herrell SD; Penson DF; Resnick MJ; Smith JA; Clark PE
    BJU Int; 2016 Feb; 117(2):260-5. PubMed ID: 25307281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrative analysis of DNA methylation and gene expression in papillary renal cell carcinoma.
    Singh NP; Vinod PK
    Mol Genet Genomics; 2020 May; 295(3):807-824. PubMed ID: 32185457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of novel prognostic alternative splicing signature in papillary renal cell carcinoma.
    Duan Y; Zhang D
    J Cell Biochem; 2020 Jan; 121(1):672-689. PubMed ID: 31407370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clear cell papillary renal cell carcinoma: micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma.
    Munari E; Marchionni L; Chitre A; Hayashi M; Martignoni G; Brunelli M; Gobbo S; Argani P; Allaf M; Hoque MO; Netto GJ
    Hum Pathol; 2014 Jun; 45(6):1130-8. PubMed ID: 24703100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The underlying molecular mechanism and potential drugs for treatment in papillary renal cell carcinoma: A study based on TCGA and Cmap datasets.
    Pang JS; Li ZK; Lin P; Wang XD; Chen G; Yan HB; Li SH
    Oncol Rep; 2019 Apr; 41(4):2089-2102. PubMed ID: 30816528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analysis of gene expression and integrin-associated signaling pathways in papillary renal cell carcinoma subtypes.
    Zhang K; Lee HM; Wei GH; Manninen A
    Oncotarget; 2016 Dec; 7(51):84178-84189. PubMed ID: 27705936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma: A Comparative Study With Papillary and Clear Cell Renal Cell Carcinomas.
    Wei S; Krause HB; Geynisman DM; Elliott A; Kutikov A; Uzzo RG; Pei J; Barata P; Carneiro B; Heath E; Ryan C; Farrell A; Nabhan C; Ali-Fehmi R; Naqash AR; Argani P; McKay RR
    Mod Pathol; 2024 Feb; 37(2):100404. PubMed ID: 38104891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
    Hänze J; Wegner M; Noessner E; Hofmann R; Hegele A
    Target Oncol; 2020 Jun; 15(3):377-390. PubMed ID: 32495158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune Cell Infiltration and Identifying Genes of Prognostic Value in the Papillary Renal Cell Carcinoma Microenvironment by Bioinformatics Analysis.
    Liu T; Zhang M; Sun D
    Biomed Res Int; 2020; 2020():5019746. PubMed ID: 32775427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathologic and Genomic Factors Associated With Oncologic Outcome in Patients With Stage III to IV Chromophobe Renal Cell Carcinoma.
    Beksac AT; Bicak M; Paranjpe I; Paulucci DJ; Sfakianos JP; Badani KK
    Clin Genitourin Cancer; 2019 Apr; 17(2):e314-e322. PubMed ID: 30639042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array.
    Albiges L; Guegan J; Le Formal A; Verkarre V; Rioux-Leclercq N; Sibony M; Bernhard JC; Camparo P; Merabet Z; Molinie V; Allory Y; Orear C; Couvé S; Gad S; Patard JJ; Escudier B
    Clin Cancer Res; 2014 Jul; 20(13):3411-21. PubMed ID: 24658158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features.
    Denize T; Just PA; Sibony M; Blons H; Timsit MO; Drossart T; Jakubowicz D; Broudin C; Morini A; Molina T; Vano Y; Auvray-Kuentz M; Richard S; Mejean A; Gimenez Roqueplo AP; Burnichon N; Verkarre V
    Mod Pathol; 2021 Mar; 34(3):647-659. PubMed ID: 32770124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.